KR102194015B1 - 정맥내 항바이러스 치료 - Google Patents

정맥내 항바이러스 치료 Download PDF

Info

Publication number
KR102194015B1
KR102194015B1 KR1020197017311A KR20197017311A KR102194015B1 KR 102194015 B1 KR102194015 B1 KR 102194015B1 KR 1020197017311 A KR1020197017311 A KR 1020197017311A KR 20197017311 A KR20197017311 A KR 20197017311A KR 102194015 B1 KR102194015 B1 KR 102194015B1
Authority
KR
South Korea
Prior art keywords
formula
compound
certain embodiments
iii
intravenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197017311A
Other languages
English (en)
Korean (ko)
Other versions
KR20190072681A (ko
Inventor
얄라가따 수타카라 바부
푸란 챈드
샨타 반티아
쉐인 아놀드
존 마이클 킬패트릭
Original Assignee
바이오크리스트 파마수티컬즈, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38169715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102194015(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2006/013535 external-priority patent/WO2007117241A1/en
Application filed by 바이오크리스트 파마수티컬즈, 인코퍼레이티드 filed Critical 바이오크리스트 파마수티컬즈, 인코퍼레이티드
Priority to KR1020207036259A priority Critical patent/KR102267754B1/ko
Publication of KR20190072681A publication Critical patent/KR20190072681A/ko
Application granted granted Critical
Publication of KR102194015B1 publication Critical patent/KR102194015B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020197017311A 2006-02-13 2007-02-12 정맥내 항바이러스 치료 Active KR102194015B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207036259A KR102267754B1 (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77274806P 2006-02-13 2006-02-13
US60/772,748 2006-02-13
USPCT/US2006/013535 2006-04-12
PCT/US2006/013535 WO2007117241A1 (en) 2006-04-12 2006-04-12 Intramuscular antiviral treatments
PCT/US2007/003755 WO2007095218A1 (en) 2006-02-13 2007-02-12 Intravenous antiviral treatments

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187005451A Division KR101992585B1 (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207036259A Division KR102267754B1 (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료

Publications (2)

Publication Number Publication Date
KR20190072681A KR20190072681A (ko) 2019-06-25
KR102194015B1 true KR102194015B1 (ko) 2020-12-22

Family

ID=38169715

Family Applications (9)

Application Number Title Priority Date Filing Date
KR1020197017311A Active KR102194015B1 (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR1020227042429A Ceased KR20230003248A (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR1020167030296A Ceased KR20160129105A (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR1020187005451A Ceased KR101992585B1 (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR20147030611A Ceased KR20140132778A (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR1020087022406A Ceased KR20080096829A (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR1020217018500A Active KR102323339B1 (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR1020217035812A Active KR102475176B1 (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR1020207036259A Active KR102267754B1 (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료

Family Applications After (8)

Application Number Title Priority Date Filing Date
KR1020227042429A Ceased KR20230003248A (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR1020167030296A Ceased KR20160129105A (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR1020187005451A Ceased KR101992585B1 (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR20147030611A Ceased KR20140132778A (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR1020087022406A Ceased KR20080096829A (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR1020217018500A Active KR102323339B1 (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR1020217035812A Active KR102475176B1 (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료
KR1020207036259A Active KR102267754B1 (ko) 2006-02-13 2007-02-12 정맥내 항바이러스 치료

Country Status (11)

Country Link
EP (1) EP1986626A1 (enExample)
JP (3) JP2009538822A (enExample)
KR (9) KR102194015B1 (enExample)
AU (2) AU2007215156A1 (enExample)
BR (1) BRPI0707769A2 (enExample)
CA (1) CA2642260C (enExample)
EA (1) EA025483B1 (enExample)
HK (1) HK1212250A1 (enExample)
MX (2) MX393640B (enExample)
MY (1) MY166063A (enExample)
WO (1) WO2007095218A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102194015B1 (ko) * 2006-02-13 2020-12-22 바이오크리스트 파마수티컬즈, 인코퍼레이티드 정맥내 항바이러스 치료
CN101367750B (zh) * 2007-08-14 2012-05-23 中国人民解放军军事医学科学院毒物药物研究所 (1s,2s,3s,4r)-3-[(1s)-1-乙酰氨-2-乙基-丁基]-4-胍基-2-羟基-环戊基-1-羧酸水合物及其医药用途
KR20220033561A (ko) 2020-09-07 2022-03-17 주식회사 경보제약 페라미비르 화합물을 포함하는 프리믹스 제형의 제약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE322163T1 (de) * 1996-06-14 2006-04-15 Biocryst Pharm Inc Substituierte cyclopentanderivate die als neuramidase-inhibitoren nuetzlich sind
AU2200199A (en) * 1997-12-17 1999-07-19 Biocryst Pharmaceuticals, Inc. Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
GB0015324D0 (en) * 2000-06-22 2000-08-16 Biota Scient Management Medicaments
KR102194015B1 (ko) * 2006-02-13 2020-12-22 바이오크리스트 파마수티컬즈, 인코퍼레이티드 정맥내 항바이러스 치료

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Antiviral Therapy. 2005. Vol. 10, No. 8, pp. 901-910*
BioCryst Pharmaceuticals의 Press Release. 2005. 12. 22.*
Phil. Trans. R. Soc. Lond. B. 2001. Vol. 356, pp. 1905-1913*

Also Published As

Publication number Publication date
KR102323339B1 (ko) 2021-11-08
KR20190072681A (ko) 2019-06-25
KR20210076189A (ko) 2021-06-23
KR20200143519A (ko) 2020-12-23
EA200870263A1 (ru) 2009-06-30
KR102475176B1 (ko) 2022-12-07
MY166063A (en) 2018-05-23
EA025483B1 (ru) 2016-12-30
MX2020002008A (es) 2020-07-13
KR20180024027A (ko) 2018-03-07
AU2013216632A1 (en) 2013-08-29
AU2013216632B2 (en) 2016-09-01
JP2013256527A (ja) 2013-12-26
KR101992585B9 (ko) 2022-09-20
WO2007095218A1 (en) 2007-08-23
JP6073202B2 (ja) 2017-02-01
KR20210135632A (ko) 2021-11-15
AU2007215156A1 (en) 2007-08-23
JP2009538822A (ja) 2009-11-12
CA2642260A1 (en) 2007-08-23
KR20160129105A (ko) 2016-11-08
KR102267754B1 (ko) 2021-06-23
CA2642260C (en) 2016-08-09
EP1986626A1 (en) 2008-11-05
MX2008010394A (es) 2009-01-12
KR20080096829A (ko) 2008-11-03
KR20230003248A (ko) 2023-01-05
BRPI0707769A2 (pt) 2011-05-10
KR101992585B1 (ko) 2019-06-25
KR20140132778A (ko) 2014-11-18
MX393640B (es) 2025-03-21
HK1212250A1 (en) 2016-06-10
JP2015180695A (ja) 2015-10-15

Similar Documents

Publication Publication Date Title
US12121503B2 (en) Antiviral treatments
KR20130103650A (ko) (ｅ)-4-카복시스티릴-4-클로로벤질설폰의 개선된 안정한 수성 제형
KR102194015B1 (ko) 정맥내 항바이러스 치료
WO2011111070A2 (en) Novel injectable combination
JP2009538822A5 (enExample)
JP2009533428A (ja) 筋肉内抗ウイルス処置
AU2016262644A1 (en) Intravenous antiviral treatments
CN115089591A (zh) 布立尼布在制备抑制肠道病毒71型嗜神经性病毒药物中的应用
KR20080113099A (ko) 근육내 항바이러스 치료
US20110015264A1 (en) Intramuscular antiviral treatments
NZ570538A (en) Intravenous antiviral treatments

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6